Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078]

ESMO Open. 2021 Jun;6(3):100137. doi: 10.1016/j.esmoop.2021.100137. Epub 2021 Jun 3.
No abstract available

Publication types

  • Published Erratum